QCG
CRNX

Quadrant Capital Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Quadrant Capital Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-230
Closed -$8.35K – 1537
2026
Q1 		$8.35K Hold
230
– – ﹤0.01% 2235
2025
Q4 		$10.7K Hold
230
– – ﹤0.01% 2187
2025
Q3 		$9.58K Buy
+230
New +$7.35K ﹤0.01% 2176
2025
Q1 		– Sell
-267
Closed -$13.7K – 2758
2024
Q4 		$13.7K Hold
267
– – ﹤0.01% 2030
2024
Q3 		$13.6K Hold
267
– – ﹤0.01% 2044
2024
Q2 		$12K Hold
267
– – ﹤0.01% 2056
2024
Q1 		$12.5K Buy
+267
New +$10.4K ﹤0.01% 2023

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quadrant Capital Group's CRNX Position: Q2 2026 in Review

Quadrant Capital Group sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2026, closing a stake of 230 shares — an estimated $8.35K sold.

Quadrant Capital Group first reported a position in CRNX in Q1 2024 and held it in 7 quarters. The position peaked at $13.7K in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Quadrant Capital Group reported no remaining Crinetics Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 230 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $8.35K.
  • Quadrant Capital Group first reported a position in Crinetics Pharmaceuticals in Q1 2024 and held it in 7 quarters.
  • Quadrant Capital Group's Crinetics Pharmaceuticals position peaked at $13.7K in Q4 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.